Results 41 to 50 of about 22,199 (155)

Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies

Bulletin of the World Health Organization, 2005
New drugs and vaccines are needed for tackling diseases of poverty in low- and middle-income countries. The lack of effective demand or market for these products translates into insufficient investment being made in research and development to meet the ...
Towse Adrian, Kettler Hannah
doaj  

Perspectives on stimulating industrial research and development for neglected infectious diseases

Bulletin of the World Health Organization, 2001
This paper summarizes recent thinking on stimulating industrial research and development (R & D) for neglected infectious diseases and argues that it is critical to enlarge the value of the market for medicines and vaccines through, for example, global ...
Webber David, Kremer Michael
doaj  

Orphan receptor GPR176 in hepatic stellate cells exerts a profibrotic role in chronic liver disease

JHEP Reports
Background & Aims: Chronic liver disease (CLD) remains a global health issue associated with a significant disease burden. Liver fibrosis, a hallmark of CLD, is characterised by the activation of hepatic stellate cells (HSCs) that gain profibrotic ...
Vincent De Smet, Elif Gürbüz, Nathalie Eysackers, Liza Dewyse, Ayla Smout, Mina Kazemzadeh Dastjerd, Pierre Lefesvre, Nouredin Messaoudi, Hendrik Reynaert, Stefaan Verhulst, Inge Mannaerts, Leo A. van Grunsven   +11 more
doaj   +1 more source

Orphan products: an emerging trend in drug approvals [PDF]

Nature Reviews Drug Discovery, 2010
Timothy, Coté, Aditya, Kelkar, Kui, Xu, M Miles, Braun, M Ian, Phillips   +4 more
openaire   +2 more sources

Drivers of Pharmaceutical Compounding: Regional Experience Analysis Using Irkutsk Pharmacy Organisations as a Case Study

Регуляторные исследования и экспертиза лекарственных средств
INTRODUCTION. National pharmacy compounding is a priority for providing the population with medicinal products, particularly the medicinal products lacking in the Russian Federation.
G. N. Kovalskaya, N. V. Verlan, E. N. Mikhalevich   +2 more
doaj   +1 more source

Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)

Biologics: Targets & Therapy, 2008
Leigh D Church1, Sinisa Savic2, Michael F McDermott21Department of Rheumatology, Division of Immunity, Infection and Inflammation, Institute for Biomedical Research, The University of Birmingham, Birmingham, UK; 2Section of Musculoskeletal Disease, Leeds
Leigh D Church, Sinisa Savic, Michael F McDermott   +2 more
doaj  

Access to Orphan Medicinal Products in Bulgaria: An Analysis of the Positive Drug List and Individual Access Schemes

Healthcare
Background/Objectives: Orphan medicinal products offer essential treatments for rare diseases, but patient access varies across European Union countries despite a common regulatory framework. In Bulgaria, access is primarily through inclusion in the positive drug list following health technology assessment or via individual access schemes under ...
Rumen Stefanov, Ralitsa Raycheva, Kostadin Kostadinov, Georgi Stefanov, Iva Zdravkova-Aneva, Elizabet Dzhambazova, Georgi Iskrov   +6 more
openaire   +2 more sources

Rheumatological complaints in H syndrome: from inflammatory profiling to target treatment in a case study

Pediatric Rheumatology Online Journal
Background H Syndrome is a rare genetic condition caused by biallelic pathogenic variants in the SLC29A3 gene. It is characterized by a wide range of clinical manifestations, many of which are related to the immune-rheumatological field.
Alessandra Tesser, Erica Valencic, Valentina Boz, Gianluca Tornese, Serena Pastore, Manuela Zanatta, Alberto Tommasini   +6 more
doaj   +1 more source

Initial lessons from public-private partnerships in drug and vaccine development

Bulletin of the World Health Organization, 2001
In recent years, venture capital approaches have delivered impressive results in identifying and funding promising health discoveries and bringing them to market.
Wheeler Craig, Berkley Seth
doaj  

Milestones On Orphan Medicinal Products Development: The 100 First Drugs for Rare Diseases Approved Throughout Europe [PDF]

Clinical Therapeutics, 2015
C. Pontes, J.M. Fontanet, M. Gomez-Valent, J. Rios Guillermo, R. Vives Vilagut, R. Morros, J. Martinalbo, J. Torrent-Farnell, F Torres   +8 more
openaire   +2 more sources